Xinhe Yuansheng Pharmaceutical

Beijing Xinhe Yuansheng Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in China, specializing in the discovery and development of innovative small molecule therapeutics for oncology. The company's primary focus is on overcoming drug resistance in cancer treatment, particularly in lung cancer. Its lead candidate, XH-001, is a fourth-generation EGFR tyrosine kinase inhibitor (TKI) designed to target the EGFR C797S mutation, which often arises after treatment with third-generation TKIs like osimertinib. Xinhe Yuansheng leverages its proprietary drug discovery platform to develop a pipeline of high-potential candidates aimed at addressing significant unmet medical needs in the global oncology market. The company is supported by prominent venture capital investors and continues to advance its clinical programs toward commercialization.